(Q31869595)

4 July 2017

title

Cilostazol suppresses intimal formation in dog grafted veins with reduction of angiotensin II-forming enzymes (English)

1 reference

4 July 2017

S Takai

1

1 reference

4 July 2017

D Jin

2

1 reference

4 July 2017

M Nishimoto

3

1 reference

4 July 2017

M Sakaguchi

4

1 reference

4 July 2017

K Kirimura

5

1 reference

4 July 2017

A Yuda

6

1 reference

4 July 2017

M Miyazaki

7

1 reference

4 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

European Journal of Pharmacology

4 July 2017

published in

1 reference

4 July 2017

volume

411

1 reference

4 July 2017

issue

3

1 reference

4 July 2017

page(s)

301-304

1 reference

Angiotensin II generation by mast cell alpha- and beta-chymases

4 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Angiotensin II-forming activity in a reconstructed ancestral chymase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter Euro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Role of chymase on vascular proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Chymase-dependent angiotensin II formation in human vascular tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Inhibition of chymase reduces vascular proliferation in dog grafted veins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

Angiotensin II receptor antagonist, L-158,809, prevents intimal hyperplasia in dog grafted veins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900864-5

10.1016/S0014-2999(00)00864-5

7 January 2021

Identifiers

DOI

1 reference

4 July 2017

1 reference